Skip to main content
Volume 9, No 3 - Summer 2009

Volume 9, No 3 - Summer 2009

Table of Contents

The Future of Inflammatory Bowel Disease Care Treatment Update
This article summarizes the David Sun Lecture at the American College of Gastroenterology in Orlando, Florida, that was delivered on October 4, 2008. The lecture, entitled “The Future Direction of IBD Care,” reviewed the future use of current drugs (such as 5-aminosalicylate, steroids, immunosuppressive medications, and biologic agents) and upcoming drugs in the treatment of IBD.[Rev Gastroenterol Disord. 2009;9(3):E69-E77 doi: 10.3909/rigd0350]
Antimicrobial Resistance and Eradication Strategies for Helicobacter pylori Treatment Update
Antimicrobial resistance is a major cause for failed Helicobacter pylorieradication. This article discusses the prevalence and mechanisms ofresistance in harboring resistant strains.H pylori and presents a strategy for eradication in patients[Rev Gastroenterol Disord. 2009;9(3):E78-E83 doi:10.3909/rigd0352]
Methylnaltrexone Bromide: New Drug for the Treatment of Opioid-Induced Bowel Dysfunction New Drug Review
Constipation is a common problem associated with opiates and opioidcompounds used for the treatment of pain and other medical conditions, andcan influence patient quality of life. Methylnaltrexone appears effective in thetherapy of opioid-induced constipation and will be useful for patients failingto respond to traditional laxative regimens.[Rev Gastroenterol Disord. 2009;9(3):E84-E93 doi: 10.3909/rigd0346]
Diarrhea News and Views From the Literature